Development of a Magnetic Nanostructure for Co-delivery of Metformin and Silibinin on Growth of Lung Cancer Cells: Possible Action Through Leptin Gene and its Receptor Regulation

Elnaz Salamni Javan1, Fatemeh Lotfi1, Davoud Jafari-Gharabaghlou1, Hanieh Mousazadeh1, Mehdi Dadashpour2,3*, Nosratollah Zarghami1,4*

Abstract

Objective: Chemotherapeutic combinational approaches would be more efficient in decreasing toxicity of drug, preventing tumor progression in relation to either drug alone. Hence, the aim of this study is to construct magnetic PLGA/PEG nanoparticles (NPs) co-loaded with Metformin (Met) and Silibinin (Sil) to investigate their cytotoxicity as well as their impact on mRNA expression levels of leptin and leptin receptor genes in A549 lung cancer cells.

Materials and Methods: The synthesized NPs were characterized by FTIR, FE-SEM, and VSM and then, MTT assay was utilized to assess and compare the cytotoxicity of various concentrations of the chemotherapeutic molecules in pure and nanoformulated forms as well as in alone and combination state after 48 h exposure time. Moreover, the mRNA levels of leptin and its receptor genes expression were studied by quantitative real-time PCR. By co-encapsulation of Met and Sil into PLGA/PEG/Fe3O4, cytotoxic efficiency of the compounds considerably augmented for all concentrations.

Results: Cytotoxicity assay displayed that combination of Met and Sil had a synergistic concentration-dependent effect on A549 lung cancer cells. Moreover, qPCR data revealed that the expression levels of the leptin and leptin receptor was considerably reduced with increasing concentrations of drug-encapsulated magnetic NPs, especially Met/Sil-encapsulated PLGA/PEG/Fe3O4 NPs. Conclusion: Present preliminary study shows that co-incorporating Met, Sil, Fe3O4 into PLGA/PEG NPs might provide a more promising and safe treatment strategy for lung cancer.

Keywords: Silibinin- Metformin- Magnetic PLGA/PEG nanoparticles- Lung cancer- Leptin

Introduction

Cancer is an uncontrolled development of cells with the potential to attack, or spread to, other tissues and organs of the body (Jeddi et al., 2019; Nikmanesh et al., 2020; Abbasi et al., 2021). Lung cancer is one of the most common and dangerous kinds of cancer throughout the world (Sheervalilou et al., 2016; Mellatyar et al., 2018). Lung cancer as a malignant tumor characterized through unchecked cell growth in the lung tissue (Adlravan et al., 2021). Different kinds of non-small cell lung cancer, are the mainly common types of lung cancer (Samadzadeh et al., 2021). Three standard therapeutic approaches of lung treatment options including surgery, chemotherapy and, radiation therapy usually are used according to the type and stage of cancer (Farajzadeh et al., 2018). But the use of some these treatment strategies are limited due to the lack of considerable progress on survival rate and the metastatic tumors (Maasomi et al., 2017). Moreover, among the therapeutic strategies, particularly chemotherapy has some undesirable side effects such as nausea, fatigue, neutropenia, anemia and hair loss (Abotaleb et al., 2018). Hence developing novel treatment methods with minimal side effects is crucial. Nowadays, various natural compounds or phytochemicals have been isolated, and their potential anti-tumor efficiency have been assessed (Farajzadeh et al., 2018; Jafari-Gharabaghlou et al., 2018). Among them, some phytochemicals such as Silibinin (Sil) and Metformin (Met) showed promising chemopreventive potential against different malignancies in both in vitro and in vivo studies (Chatran et al., 2018; Amirsaadat et al., 2021).

Sil, a flavonoid derived from Silybum marianum, has been thoroughly assessed for preventing the development of considerable progress on survival rate and the metastatic tumors (Maasomi et al., 2017). Moreover, among the therapeutic strategies, particularly chemotherapy has some undesirable side effects such as nausea, fatigue, neutropenia, anemia and hair loss (Abotaleb et al., 2018). Hence developing novel treatment methods with minimal side effects is crucial. Nowadays, various natural compounds or phytochemicals have been isolated, and their potential anti-tumor efficiency have been assessed (Farajzadeh et al., 2018; Jafari-Gharabaghlou et al., 2018). Among them, some phytochemicals such as Silibinin (Sil) and Metformin (Met) showed promising chemopreventive potential against different malignancies in both in vitro and in vivo studies (Chatran et al., 2018; Amirsaadat et al., 2021).

Sil, a flavonoid derived from Silybum marianum, has been thoroughly assessed for preventing the...
growth of different malignancies via wide in vitro and in vivo examinations. Sil alone and in combination with other chemotherapeutic molecules exhibited effective anticancer activity via inhibition of cancer cell proliferation, angiogenesis and epigenetic-associated processes (Pourgholi et al., 2021). Met is a standard clinical drug to choose for treating polycystic ovary syndrome and type 2 diabetes mellitus (Mogheri et al., 2021). In vivo and in vitro researches have exposed that Met has a direct anticancer effect through decreasing the proliferation and triggering the apoptosis of cancer cells (Zakikhani et al., 2006). Recent advances for efficient treatment of cancer are based on an combination of various chemotherapeutic molecules with different mechanism of actions (Dai et al., 2017). Besides, suppressing a single target does not definitely eradicate cancer cell, thus applying a combination of molecular-targeted drugs have been reported (Nagaraj and Datta, 2010). Combination therapy, mainly in the elimination of obstacles such as tumor resistance and low drug effectiveness can be effective to achieve better clinical outcomes to the single drug (Cukierman and Khan, 2010). Leptin, a product of Ob gene secreted by adipose tissue that balances the regulation between orexigenic and anorexigenic by binding to hypothalamic receptors and controls appetite, energy expenditure, and body mass composition (Ahima and Flier, 2000). The role of leptin in lung cancer is not clear (Dutta et al., 2012).

Primary findings proved the presence of ObR1 in squamous cell carcinoma (SCC) of the lung and human lung tissue in which leptin lead to an increase in cell growth through the ERK1/2 pathway (Tsuchiya et al., 1999). Besides, it was found that ERK1/2 pathway is induced in A549 cells via leptin (Xu et al., 2018).

Numerous studies have showed that polymeric nanoparticles (NPs) significantly contribute for improving the co-delivery efficiency of chemotherapeutic agents due to their easy penetration into cell membranes, decreasing the off-target effects, and lysosomal escaping following endocytosis (Hashemi et al., 2021; Mousazadeh et al., 2021). As a biomaterial approved by FDA, poly lactic-co-glycolic acid (PLGA) is known for biocompatibility and ability to biodegrade due to its long-term clinical trials (Firouzi-Amandi et al., 2018; Javan et al., 2019). The structure and the solubility of drug molecules-controlled drug release rate. Moreover, the hydrophilic block of polyethylene glycol (PEG) has showed great potential in decreasing the protein adsorption, opsonization and subsequent clearance as well as increasing blood circulation. There have been significant achievements in the application of NPs in disease diagnostic and highly efficient targeted therapy, it is vital that the systems are biocompatible and capable of being multifunctional for recognition of specific target tumor sites (Serati-Nouri et al., 2021). In the current work, we aimed to evaluate the cytotoxicity efficiency of Met and Sil co-encapsulated into PLGA/PEG/Fe₃O₄ NPs against A549 human lung cancer cells. Also, the impact of the co-loaded magnetic PLGA/PEG NPs on the expression of leptin and leptin receptor genes as a possible molecular mechanism of their anticancer activity were investigated.

Materials and Methods

Materials
The A549 lung cell line (lung adenocarcinoma cells) obtained from National Center for Genetic and Biological Resources of Iran. FeCl₂. 4H₂O, FeCl₃.6H₂O and Ammonia solution (25wt %) were obtained from Fluka (Buchs, Switzerland). Silibinin, Metformin, Roswell Park Memorial Institute (RPMI) 1640, Fetal Bovine Serum (FBS), MTT powder, Streptomycin/penicillin, dimethyl sulfoxide (DMSO) and dichloromethane (DCM) were gained from from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Preparation of PLGA/PEG/Fe₃O₄ NPs
The ring-opening polymerization method was utilized to synthesize of PLGA–PEG copolymers. Pre-determined quantity of glycolide, D, L-lactide, and PEG4000 were melted at 120°C under nitrogen. Next, Sn(Oct)₂ (0.01 mmol) was added and the polymerization reaction was continued for 2 h (Yang et al., 2006). Next, the generated product was dissolved in dichloromethane, and finally, the precipitation process followed in cold diethyl ether solvent.

Preparation of drug-loaded NPs
For encapsulation of Met/Sil in PLGA/PEG/Fe₃O₄ NPs, double emulsion method was utilized. Firstly, PLGA/PEG (250 mg) was dissolved in in dichloromethane (DCM, 5 ml). PVA (20 ml, 0.5% w/v) including Met and Sil (20 mg) was added to the organic phase and emulsified with sonicator probe with the power of 10 W for 45 seconds to produce w/o/w emulsion. Then, to evaporate the organic phase, the obtained emulsion was stirred in room temperature and the remaining solution was centrifuged for 40 minutes at 15,000 rpm and freeze-dried for the elimination of all of the residual solvents.

NPs characterization
The field emission scanning electron microscopy (FE-SEM) (MIRA3 TESCAN, Czech) was applied to determine NPs morphology The Dynamic Light Scattering (DLS) was utilized to analyze the NPs average size. The structure confirmation of PLGA/PEG/Fe₃O₄ NPs was investigated via Fourier transform infrared (FTIR) spectroscopy (BRUKER series). The Vibrating Sample Magnetometer (VSM) is based on vibrating a sample magnetometer (VSM; Lakeshore Cryotronics, Westerville, OH) magnetization curves were measured at room temperature.

In vitro release study
The behavior discharge of agents from magnetic NPs was studied at pH 7.4. 3 mg of Met/Sil encapsulated magnetic NPs was scattered in 20 mL PBS and added in a dialysis tubing, and then incubated at 37°C with stirring at 70 rpm. Predetermined time points, 2mL of fresh PBS was added to keep the constant volume to each sample. The released of Met and Sil measured using Lambda 950 Visible-UV spectrophotometer at 237 and 288 nm and the Met and Sil released concentration was calculated according to the standard curve.
Drug encapsulation efficiency and drug loading

To determine the efficiency of drug encapsulation, after the synthesis of drug-loaded NPs, the supernatant of the tube was isolated and the quantity of non-entrapped drugs assessed via was defined using Visible-UV spectrophotometer at 237 and 288 nm wavelength for Sil and Met respectively. In the following, the percent of entrapped drug (Encapsulation Efficiency; EE) and drug loading (DL) were computed by employing the following formulas:

\[
DL(\%) = \frac{\text{Amount of drug entrapped}}{\text{Amount of NP}} \times 100 \quad (1)
\]

\[
EE(\%) = \frac{\text{Amount of drug entrapped}}{\text{Amount of drug added}} \times 100 \quad (2)
\]

Cytotoxicity Assay

The A549 lung cell line were cultured in RPMI-1640 media plus 10% FBS and 1% streptomycin/penicillin and incubated at 5% humidity in sterile flasks. MTT assay was utilized to study the viability of cells. Briefly, A549 lung cancer cells (7,000/well) were seeded in 96-well plates and incubated to help cell attachment. After 24 h, cells were exposed to Met, Sil, Met/Sil, Met-loaded PLGA/PEG/Fe₃O₄ NPs, Sil-loaded PLGA/PEG/Fe₃O₄ NPs, Met/Sil-loaded PLGA/PEG/Fe₃O₄ NPs for 48 h. Next, MTT solution (0.5 mg/mL, 200 µL) was added to all wells and incubated for 4 hours. After incubation for 4 h at 37°C, the medium was evacuated and DMSO (100 µL) was included in each well. Finally, rate of absorbance was assessed through a microplate reader (Star fax 3200 (Awareness Technology Inc.) at 570 nm. The data on mean± SD (n = 3) were displayed in each test.

Real-time PCR assay

A549 cells were plated into 6-well plate and treated with free and nanofurnished drugs for 48 h and and total RNA was extracted using RNaseasy mini kit (Qiagen, USA) according to the manufacturer’s procedure. RNA quality and quantity determined by a NanoDrop (ThermoScientific, USA). For the cDNA synthesis, an appropriate proportion of RNA was taken from each sample and reverse transcribed through RevertAid First strand cDNA synthesis Kit (Fermentas, St Leon-Rot, Germany). Real-Time PCR system was followed using Syber Green Master Mix (BioMolecular Systems, Australia) for the target genes applying the selected primers. Relative expression of each gene was normalized via housekeeping gene (GAPDH) and quantified utilizing $2^{-\Delta\Delta C_{\text{t}}}$ method. All the experiments were done in triplicate.

After treating A549 cells with different concentrations of the NPs for 48 h. Total RNA was extracted using TRIZol reagent (Invitrogen, USA). According to producer’s instructions, Nanodrop was verified the purity and quantity of total RNA. RevertAid™ First Strand cDNA synthesis kit (Thermo Fisher Scientific, MA, USA) was used for synthesizing cDNA from 1 µg RNA. Finally, the $2^{-\Delta\Delta C_{\text{t}}}$ method was applied to determine the relative quantification and the gained data were normalized to the levels of the β-actin gene as a housekeeping control.

Statistical analysis

Statistical significance was done using GraphPad Prism® version 8.0 software, USA. The results were evaluated using one-way ANOVA Analysis of Variance. All the samples were analyzed in triplicates and the results provide as mean ± standard deviation (SD) for n = 3. The level of significance was considered by p-value. Statistically, P value <0.05 was considered significant.

Results

Characterization of nanoparticles

Spherical morphology homogeneously distributed without any significant aggregation in the synthesized NPs was confirmed via FE-SEM analysis. The micrographs of Met/Sil-encapsulated PLGA/PEG/Fe₃O₄ NPs are shown in Figure 1. The sizes of Met/Sil-loaded PLGA/PEG/Fe₃O₄ NPs were about 160-220 nm. The dispersion of the NPs was greatly improved. DLS data analysis showed a
uniform distribution of particles with an average size of 140 nm, a polydispersity index of 0.157 and zeta potential of $-23.4 \pm 3.6$ mV for PLGA/PEG/Fe$_3$O$_4$ NPs. Moreover, it was found that PLGA/PEG/Fe$_3$O$_4$ NPs loaded with Met and Sil had an average size of 180 and 190 nm, respectively.

Chemical structures of the synthesized NPs were studied by FTIR spectroscopy (Figure 2). The stretching vibration mode of Fe–O bonds in Fe$_3$O$_4$ assigned to the absorption peaks at 720 cm$^{-1}$. The absorption band at 3509.9 cm$^{-1}$ belonged to hydroxyl groups at the PEG end in the copolymer from which PEG homopolymer has been eliminated. The bands at 2885 cm$^{-1}$ due to stretch vibration C–H, and a strong band at 1635 cm$^{-1}$ is due...
to C=O stretch. Absorption at 1090.6 cm\(^{-1}\) belonged to C–O stretch. These absorption bands indicate that the encapsulation of drugs in magnetic nanoparticles was successful.

To measure the magnetic futures of the pure Fe\(_3\)O\(_4\) NPs and Sil/Met encapsulated in PLGA/PEG/F\(_3\)O\(_4\) NPs, a vibrating sample magnetometer (VSM) technique was used at room temperature. According to the hysteresis curve in Figure 3A, the saturation value of magnetization of the pure Fe\(_3\)O\(_4\) NPs was found to be 56 emu/g. Also, in Figure 3B, the saturation value of magnetization of the Sil/Met-encapsulated PLGA/PEG/Fe\(_3\)O\(_4\) NPs is lower than the saturation value of magnetization of the pure Fe\(_3\)O\(_4\) NPs presented (9 emu/g). This difference indicates that the co-encapsulation of Fe\(_3\)O\(_4\), Sil and Met in PLGA/PEG copolymers was successful. After the elimination of the magnetic field, no magnetic activity was observed in the magnetic polymer NPs. This property of magnetic NPs is very important in its applications in biomedical and bioengineering fields.

**Drug release profile**

In this study, the release rate of Met and silibinin from Met/Sil-loaded PLGA/PEG/Fe\(_3\)O\(_4\) NPs were investigated at pH 7.4 (Figure 4) Up to 180 hours, the release rate of Sil and MET from the the nanoparticulate drug release systems were about 65% and 85% respectively. Both therapeutical molecules have been shown to exhibit an initial

Figure 4. Discharge Profile of Sil and Met from Met/Sil-loaded PLGA/PEG/Fe\(_3\)O\(_4\) NPs at pH 7.4. The data are presented as mean ± SD (n =3).
burst release for the first 8 hours followed with slow release rate. Furthermore, the results showed that the release of hydrophilic Sil molecules from the NPs were slower than hydrophilic Met molecules.

**Drug loading (DL) and determination of the entrapment efficiency (EE)**

Nanoencapsulation efficiency plays very essential role in delivery of drug by NPs. The nanoencapsulation efficiency of Met, Sil and Sil/Met were found to be 75.4 ± 2.6%, 83.28% and 85.39%, respectively. Moreover, the capacity of drug loading of Sil and Met found to be 13.6 ± 3.1% and 12.3 ± 4.2%, respectively. It seems that the high encapsulation efficacy of these natural antitumor drugs is due to their hydrophobic nature.

**Cell viability**

Based on the IC_{50} obtained from the cytotoxicity assay, data analysis showed that IC_{50}s of pure Met, pure Sil, pure Met/Sil, Met-loaded PLGA/PEG/ Fe_{3}O_{4} NPs, Sil-loaded PLGA/PEG/ Fe_{3}O_{4} NPs, and Met/Sil-loaded PLGA/PEG/ Fe_{3}O_{4} NPs on A549 lung cancer cell line is 14.31 mM, 35.92 μM, 17.63, 26.37, 12.03, 10.51 μM for 48 h MTT assays (Figure 5), respectively. These finding for the treatment of A549 cells, different concentrations of pure Met, pure Sil, and nanocapsulated in PLGA/PEG/ Fe_{3}O_{4} NPs have an inhibitory effect on cancer cells at 48 hours. With increasing concentration, the toxicity of nano-encapsulated Met and Sil was higher than the toxicity of pure Met and pure Sil. The effect of the combination agent at 48 hours showed that the synergistic combinations of two agents had a higher synergistic effect compared to the individual agent as well as were able to overcome toxicity and other side effects of single agent (P<0.05) which express an interaction between the two agents. Therefore, these results revealed that the use of this agents in the form of pure and nanocapsulated, even at the lowest dilution, have synergistic effects.

**Gene expression analysis**

Real-time PCR was used to quantify leptin gene expression in A549 cell line treated with pure and magnetic nanoform of Met and Sil (Figure 6). GAPDH region normalized and calculated by the 2^{−ΔΔCT} method to assess the level of leptin and leptin receptor gene expression changes between the control and treated A549 cells. The expression level of leptin and its receptor genes were declined by all types of treatments. It was found that nano-encapsulated forms of Met and Sil in PLGA/PEG/ Fe_{3}O_{4} NPs significantly decreased leptin gene expression as compared to alone and combination forms of chemotherapeutic molecules. the highest decrease in leptin and its receptor gene expressions were detected on the cells treated with Met/Sil-loaded PLGA/PEG/ Fe_{3}O_{4} NPs.

**Discussion**

To reduce deaths from lung cancer, expand new treatments or prevent them is very important. The importance of targeted drug delivery for antitumor drug and suppressing side effects on normal cells is essential (Akbari et al., 2021). Combination therapy is of great interest due to the synergistic effect of the drugs (Moorthi and Kathiresan, 2013). The use of Sil as a potential compound in the treatment of various cancers have reported by many researches (Singh and Agarwal, 2006). These effects appear to be due to the ability of Sil to suppress cell proliferation, prevent cell division, increase expression of cell cycle inhibitors, increase apoptosis and suppress transcription factors (Singh and Agarwal, 2006). Some of the signaling pathways affected by Sil are MAPK and AKT (Singh and Agarwal, 2004). Met exerts its anticancer effect by activating the AMPK pathway . Met prevents cancer cell mitosis by inducing immune activation and thereby reducing growth factor signaling (Faramarzi et al., 2019). MicroRNA222 suppression induced by Met administration leads to increased levels of p27 and p57 molecules and consequently disrupts cell cycle in tumor cell . Leptin is made by adipose tissue in the human body and released into the blood(D’Marco et al., 2020) . Magnetic NPs can be used in the treatment of cancer cells through hyperthermia (Kobayashi, 2011). One of the approaches is used in the treatment of cancer is magnetic hyperthermia,
the fluid containing Magnetic NPs is injected into the cancerous tissue (Thiesen and Jordan, 2008). By creating an alternating magnetic field, these particles vibrate and generate heat, increasing the temperature of the cancerous tissue (Latorre and Rinaldi, 2009). This method will make chemotherapy work better (Salloum et al., 2008). As a result, it raises the temperature of tissue to 4 and causes the cancer cells to be completely destroyed (Johannsen et al., 2010). Research has shown that the use of magnetic NPs causes the entire cancer tissue to be affected by heat (Deatsch and Evans, 2014). Leptin reduces the production of the hypothalamic neuropeptide Y, which is a potent stimulus of appetite (thereby reduces appetite) (Shen et al., 2009). The leptin receptor is a membrane receptor belonging to the class 1 cytokine family Leptin exerts its function through it (Bain et al., 2014). Both leptin and its receptor are involved in mitogenic factors in breast cancer (Artac and Altundag, 2012). Therefore, they can be considered as targets for the treatment of lung cancer.

As the impact of NPs size on the biopharmaceutical aspects and discharge efficiency of drug, it was evaluated by DLS and SEM observations (Mollazade et al., 2011). Also, it has been suggested that most cells are capable of passing NPs with a diameter smaller than 400 nm through their membranes. In terms of charge the surface chemistry of NPs play a crucial role in influencing the stability amount of NPs emulsions and the interaction between the cell membrane and NPs (Mohandesnezhad et al., 2020). The higher zeta potential value causes natural colloidal, long term stability of NPs due to negative repulsion. Therefore, it seems that the measurement of Met and Sil loaded PLGA/PEG/ FeOx NPs will be acceptable for achieving longevity in blood and passive targeting mechanism of cancer cells. There was an important difference between the treated and control cells in the levels of leptin and leptin receptor gene expression, both of which were declined in the treated cells in relative to the control cells (Nejati-Koshki et al., 2014). Magnetic NPs can be used in therapeutic cancer cells by hyperthermia and agents can be loaded into magnetic NPs and used in targeted cancer treatment (Sivakumar et al., 2014; Nejati et al., 2021). Previous research has shown that the combination of Magnetic NPs with Met or Sil with other drugs has potent anti-cancer effects on cancer cells (Rasouli et al., 2020). The results of the present study were also in line with the results of the above research. The combination of Met and Sil with increased suppression of leptin gene expression in a cellular model of lung cancer. In this study, cytotoxicity assay showed that Met and Sil had a lethal effect on A549 cells in a concentration-dependent manner and nano-Met/Sil significantly reduced IC50 in 48 h. With increasing concentration, nano-encapsulated forms of Met and Sil have been shown to be more toxic than pure Met and Sil. The effect of the combination drug after 48 hours showed that the combination of the two drugs had a higher synergistic effect compared to the single drug. The results have shown that the use of these compounds were pure and nano encapsulated, even at the lowest dilution with a synergistic effect. Real-time PCR results revealed that Met and Sil inhibited leptin and its receptor gene expression in a dose-dependent manner. In addition, Met and Sil co-loaded in PLGA/PEG/ FeOx NPs significantly reduced the expression level of the leptin and its receptor gene.

In conclusion, in the current work, magnetic PLGA/PEG loaded with Met and Sil were developed to examine the impact of Met and Sil on growth and proliferation of lung cancer cells. Based on our results magnetic PLGA/PEG loaded with Met and Sil was able to kill lung cancer cells more rapidly than other groups, thus potentially this strategy can decrease side effects and cytotoxicity. Furthermore, according to our outcomes nano-formulation of Met and Sil with magnetic PLGA/PEG can suppress leptin gene expression and its receptor of human lung cancerous A549 cells more that free form, therefore nano-coencapsulated state of Met and Sil has significant potential to use as complement drug for treatment of lung cancer. These results imply that loading of Met and Sil in magnetic PLGA/PEG NPs as we have displayed here could result in hopeful candidates for treatment of lung cancer with a specific final goal of reducing drug resistance related to the current clinically used therapeutics.

Author Contribution Statement

SE and LF as the main colleague contributed to performing experiments, data analysis, and manuscript writing; JD and MH as main colleagues were involved in manuscript writing; DM and ZN as the executive of the project was involved in conception and design, manuscript writing, and supervised the manuscript preparation.

Acknowledgments

Also, authors would like to thank the Stem Cell Research Center for the use of their laboratory facilities.

Funding

This study was financially supported by grant No: 995537 of the National Institute for Medical Research Development

Conflict of Interest

The authors declare that they have no competing interests.

References


Anticancer Effects of Silibinin-Metformin Magnetic Nanostructured in Lung Cancer Cells

DOI:10.31557/APJCP.2022.23.2.519

mesoporous silica nanoparticles/electrospun nanofibers. Life Sci, 285, 119947.


Singh RP, Agarwal R (2006). Prostate cancer chemoprevention by silibinin: bench to bedside. Molecular Carcinogenesis: Published in cooperation with the University of Texas MD Anderson Cancer Center, 45, 436-42.


This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.